drugset / Trial / NCT02553603

The Effect of Growth Hormone Releasing Hormone on Cognitive Function in Individuals With Mild Cognitive Impairment

NCT02553603

RandomizedParallel-groupTriple-blindTreatment

Summary

This study is examining the effects of growth hormone releasing hormone (GHRH) on mild cognitive impairment (MCI). GHRH will be given at a dose of 1mg/day for 10 weeks to subjects with MCI as well as healthy controls.

Timeline

Start
2017-07-18
Primary completion
2019-01-17
Completion
2019-01-17

Drugs

EvaluationDrugModalityDoseRoute
Subject Tesamorelin Peptide 1 mg